Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF and EPO with Zidovudine in AIDS/ARC
NCT00002281Phase 2Completed
- Sponsor
- Amgen
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial of filgrastim and epoetin alfa in neutropenia and anemia (3 arms), sponsored by Amgen. Primary endpoints: Safety and Tolerance and Biological Activity. Status: completed.
02
Drugs
filgrastimepoetin alfa
03
Conditions
neutropeniaanemia
Beyond the preview
Go deeper on NCT00002281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002281.